Skyrizi vs Tremfya
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Skyrizi | US Tremfya |
|---|---|---|
| Generic name | risankizumab-rzaa Unverified catalogue summary (Generic name) for Skyrizi in US; not checked against current local product information. | guselkumab Unverified catalogue summary (Generic name) for Tremfya in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Skyrizi in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Tremfya in US; not checked against current local product information. |
| Treats | Plaque psoriasis, psoriatic arthritis, Crohn's disease Unverified catalogue summary (Treats) for Skyrizi in US; not checked against current local product information. | Plaque psoriasis, psoriatic arthritis Unverified catalogue summary (Treats) for Tremfya in US; not checked against current local product information. |
| Category | Autoimmune Unverified catalogue summary (Category) for Skyrizi in US; not checked against current local product information. | Autoimmune Unverified catalogue summary (Category) for Tremfya in US; not checked against current local product information. |
| Manufacturer | AbbVie Unverified catalogue summary (Manufacturer) for Skyrizi in US; not checked against current local product information. | Janssen Unverified catalogue summary (Manufacturer) for Tremfya in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Skyrizi in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Tremfya in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Skyrizi in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Tremfya in US; not checked against current local product information. |
| Est. TV ad spend | $480M | $140M |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Skyrizi in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Tremfya in US; not checked against current local product information. |
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Skyrizi or Tremfya better?
This directory does not compare clinical effectiveness or safety. Listing Skyrizi and Tremfya together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Skyrizi and Tremfya?
The table shows catalogue identification and estimated advertising information for Skyrizi and Tremfya, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Skyrizi has the larger estimated TV advertising budget of the two.